Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine in individuals aged 16-26 years in Chongqing, China
ABSTRACTThe safety of human papillomavirus (HPV) vaccines, one of the major challenges to public vaccination, has been controversial. This study assessed the adverse reactions of 9-valent HPV (9vHPV) vaccines. This open-label, observational, multi-center, post-marketing study assessed the safety of...
Saved in:
Main Authors: | Yuan-yuan Zhang (Author), Jia-Wei Xu (Author), Yang Liu (Author), Wei Qiu (Author), Pei-Ning Bai (Author), Yi Zeng (Author), Qing Wang (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine: Comment
by: Hinpetch Daungsupawong, et al.
Published: (2024) -
Extended surveillance to assess safety of 9-valent human papillomavirus vaccine
by: Maria E. Sundaram, et al.
Published: (2022) -
Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine: a retrospective real-world study in China
by: Ruogu Meng, et al.
Published: (2023) -
Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
by: E. D. Moreira, et al.
Published: (2018) -
Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
by: Yuan Ding, et al.
Published: (2023)